Neuraxis (NRXS) Asset Writedowns and Impairment (2022 - 2025)
Neuraxis (NRXS) posted Asset Writedowns and Impairment of $126.0 for Q4 2025, up 101.2% sequentially from -$10541.0 in Q3 2025, and up 100.67% YoY from $62.79 in Q4 2024.
Neuraxis (NRXS) Asset Writedowns and Impairment (2022 - 2025) Analysis & Trends
Neuraxis has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $126.0 in Q4 2025.
- Quarterly Asset Writedowns and Impairment rose 100.67% year-over-year to $126.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$25962.0 (down 682.89% YoY) and the FY2025 annual result came in at $2326.0, down 47.78% from the prior year.
- Asset Writedowns and Impairment rose to $126.0 in Q4 2025 per NRXS's latest filing, from -$10541.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $21307.0 in Q2 2022 and troughed at -$23290.0 in Q4 2022.
- A 4-year average of $2350.2 and a median of $3155.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
- The sharpest annual moves came in 2024 and 2025: Asset Writedowns and Impairment jumped 460.02% in 2024, then plunged 434.1% in 2025.
- Over 4 years, Asset Writedowns and Impairment stood at -$23290.0 in 2022, then surged by 181.16% to $18901.0 in 2023, then plunged by 198.95% to -$18702.0 in 2024, then jumped by 100.67% to $126.0 in 2025.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $126.0, -$10541.0, and -$18702.0 for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 126.00 |
| Dec 31, 2025 | 126.00 |
| Sep 30, 2025 | -10,541.00 |
| Sep 30, 2025 | -10,541.00 |
| Dec 31, 2024 | -18,702.00 |
| Dec 31, 2024 | -18,702.00 |
| Sep 30, 2024 | 3,155.00 |
| Sep 30, 2024 | 3,155.00 |
| Jun 30, 2024 | 6,367.00 |
| Jun 30, 2024 | 6,367.00 |
| Mar 31, 2024 | 13,634.00 |
| Mar 31, 2024 | 13,634.00 |
| Dec 31, 2023 | 18,901.00 |
| Dec 31, 2023 | 18,901.00 |
| Sep 30, 2023 | 2,453.00 |
| Sep 30, 2023 | 2,453.00 |
| Jun 30, 2023 | 7,714.00 |
| Jun 30, 2023 | 7,714.00 |
| Mar 31, 2023 | -3,787.00 |
| Mar 31, 2023 | -3,787.00 |